MedDRA preferred term

Poor quality sleep: adverse event reports recording this term

21,114 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

21,114
reports recording the term: 0.1% of all reports; 1,325
reports, 12 months to June 2026: 1,447 in the 12 months before; 54.2%
marked serious by the reporter: 57.4% across all reports; 1.9%
record death among outcomes, as reported: 9.1% across all reports

21,114 reports in FDA's adverse event database record the MedDRA term "Poor quality sleep": 0.1% of all reports received between April 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,325 reports recorded it in the 12 months to June 2026, close to the 1,447 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 54.2% are marked serious, 1.9% include death among the outcomes and 19% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humira, Xyrem and Chantix. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Humira	—	611	0.1%
Xyrem	Central nervous system depressant	595	1%
Chantix	Partial cholinergic nicotinic agonist	369	0.5%
Enbrel	Tumor necrosis factor blocker	320	0.1%
Lyrica	—	318	0.3%
Prednisone	Corticosteroid	300	0.2%
Methotrexate	Folate analog metabolic inhibitor	299	0.1%
Lumryz	Central nervous system depressant	280	8%
Xeljanz	Janus kinase inhibitor	246	0.2%
Carbidopa levodopa	Aromatic amino acid	240	1.2%
Tysabri	Integrin receptor antagonist	225	0.1%
Belsomra	Orexin receptor antagonist	215	2.3%
Rozerem	Melatonin receptor agonist	203	6.3%
Revlimid	Thalidomide analog	186	0.1%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	184	0.4%
Dupixent	Interleukin-4 receptor alpha antagonist	172	0%
Seroquel	Atypical antipsychotic	168	0.3%
Entresto	Angiotensin 2 receptor blocker	159	0.2%
Ibrance	Kinase inhibitor	159	0.2%
Montelukast	Leukotriene receptor antagonist	157	1.2%
Xolair	Anti-IgE	154	0.2%
Hetlioz	Melatonin receptor agonist	152	2.7%
Fluoxetine	Serotonin reuptake inhibitor	141	0.5%
Nuplazid	Atypical antipsychotic	141	0.3%
Forteo	Parathyroid hormone analog	140	0.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	1,188	0.2%	0.1%
Corticosteroid	919	0.1%	0.1%
Central nervous system depressant	908	1.2%	0.7%
Kinase inhibitor	787	0.1%	0%
Tumor necrosis factor blocker	769	0.1%	0.1%
Serotonin reuptake inhibitor	701	0.3%	0.2%
Nonsteroidal anti-inflammatory drug	594	0.1%	0%
Serotonin and norepinephrine reuptake inhibitor	478	0.3%	0.2%
Janus kinase inhibitor	451	0.1%	0%
Opioid agonist	413	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.5%102

2 to 111.8%376

12 to 170.8%164

18 to 4413.7%2,893

45 to 6424.4%5,162

65 to 7411.8%2,493

75 and over8.7%1,837

Age not given38.3%8,087

Patient sex

Female59.1%12,484

Male32.5%6,864

Not given8.4%1,766

Grey bar: all 20,646,523 reports in the database. 67.3% of these reports give the United States as the country.

Questions about "Poor quality sleep"

What does "Poor quality sleep" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record poor quality sleep?

21,114 reports through June 2026 (0.1% of all reports), 1,325 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humira (611), Xyrem (595), Chantix (369), Enbrel (320) and Lyrica (318). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.